The role of cardiac autonomic function in hypertension and cardiovascular disease

2009 ◽  
Vol 11 (3) ◽  
pp. 199-205 ◽  
Author(s):  
Paolo Palatini ◽  
Stevo Julius
Keyword(s):  
Cardiovascular Disease ◽  
Autonomic Function ◽  
Cardiac Autonomic Function

Improving the prognosis of renal patients: the role of blood flow‐restriction resistance training on redox balance and cardiac autonomic function

2021 ◽  
Author(s):  
Lysleine Alves Deus ◽  
Rodrigo Vanerson Passos Neves ◽  
Hugo de Luca Corrêa ◽  
Andrea Lucena Reis ◽  
Fernando Sousa Honorato ◽  
...  
Keyword(s):  
Blood Flow ◽  
Resistance Training ◽  
Autonomic Function ◽  
Redox Balance ◽  
Blood Flow Restriction ◽  
Cardiac Autonomic Function ◽  
Flow Restriction

scholarly journals Autonomic dysfunction: A comparative study of patients with Alzheimer’s and frontotemporal dementia – A pilot study

2017 ◽  
Vol 08 (01) ◽  
pp. 084-088 ◽  
Author(s):  
Thomas Gregor Issac ◽  
Sadanandavalli Retnaswami Chandra ◽  
Neelesh Gupta ◽  
Malligurki Raghurama Rukmani ◽  
S. Deepika ◽  
...  
Keyword(s):  
Frontotemporal Dementia ◽  
Autonomic Dysfunction ◽  
Autonomic Function ◽  
Total Power ◽  
Cardiac Autonomic Function ◽  
The Mean ◽  
Function Testing ◽  
Insight Into ◽  
Diagnostic Importance

ABSTRACT Introduction: In frontotemporal dementia (FTD) and Alzheimer’s disease (AD), central autonomic structures get affected early. An insight into autonomic functions in these patients is likely to be of diagnostic importance and thus help in prognosticating and also probably explain unexplained sudden death in some of these patients. Objectives: The objective of this study is to identify autonomic dysfunction prevailing in patients. Then, if there is dysfunction, is the pattern same or different in these two conditions. And if different it will serve as an additional biomarker for specific diagnosis. Patients and Methods: There were 25 patients and 25 controls and six patients and three controls in AD and FTD groups, respectively. The participants who were recruited were assessed for heart rate variability and conventional cardiac autonomic function testing. The parameters were analyzed using LabChart version 7 software and compared with control population using appropriate statistical methods using SPSS version 22 software. Results: The mean overall total power was low in the FTD group (P < 0.001), and there was significant reduction in the standard deviation of normal-to-normal intervals and root mean square of successive differences (P < 0.001) with elevated sympathovagal balance in the FTD group (P = 0.04). Patients with AD also showed sympathetic dominance, but there was in addition parasympathetic suppression unlike in the FTD group. Conclusion: This study reveals autonomic dysfunction in patients with FTD and AD. Both conditions show sympathetic dominance, probably consecutive to the involvement of central autonomic regulatory structures as a shared domain. It remains to be confirmed if these findings are the cause or effect of neurodegeneration and might open up newer territories of research based on the causal role of neurotransmitters in these regions and thus lead to novel therapeutic options such as yoga. The presence of parasympathetic suppression in AD in addition helps differentiate these two conditions.

scholarly journals Abnormal Cardiac Autonomic Regulation in Mice Lacking ASIC3

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Ching-Feng Cheng ◽  
Terry B. J. Kuo ◽  
Wei-Nan Chen ◽  
Chao-Chieh Lin ◽  
Chih-Cheng Chen
Keyword(s):  
Heart Rate ◽  
Autonomic Function ◽  
Physiological Role ◽  
Autonomic Regulation ◽  
Pcr Analysis ◽  
Baseline Heart Rate ◽  
Cardiac Autonomic Function ◽  
Sympathetic Function ◽  
Cardiac Autonomic Regulation

Integration of sympathetic and parasympathetic outflow is essential in maintaining normal cardiac autonomic function. Recent studies demonstrate that acid-sensing ion channel 3 (ASIC3) is a sensitive acid sensor for cardiac ischemia and prolonged mild acidification can open ASIC3 and evoke a sustained inward current that fires action potentials in cardiac sensory neurons. However, the physiological role of ASIC3 in cardiac autonomic regulation is not known. In this study, we elucidate the role of ASIC3 in cardiac autonomic function usingAsic3−/−mice.Asic3−/−mice showed normal baseline heart rate and lower blood pressure as compared with their wild-type littermates. Heart rate variability analyses revealed imbalanced autonomic regulation, with decreased sympathetic function. Furthermore,Asic3−/−mice demonstrated a blunted response to isoproterenol-induced cardiac tachycardia and prolonged duration to recover to baseline heart rate. Moreover, quantitative RT-PCR analysis of gene expression in sensory ganglia and heart revealed that no gene compensation for muscarinic acetylcholines receptors and beta-adrenalin receptors were found inAsic3−/−mice. In summary, we unraveled an important role of ASIC3 in regulating cardiac autonomic function, whereby loss of ASIC3 alters the normal physiological response to ischemic stimuli, which reveals new implications for therapy in autonomic nervous system-related cardiovascular diseases.

scholarly journals 101 Role of cardiac autonomic function in pathophysiology of permanent AF

2021 ◽  
Author(s):  
Ahsan Khan ◽  
Rehan Junejo ◽  
Neil Thomas ◽  
James Fisher ◽  
G. Lip
Keyword(s):  
Autonomic Function ◽  
Cardiac Autonomic Function

Telmisartan in High Cardiovascular Risk Patients

2012 ◽  
Vol 8 (1) ◽  
pp. 10 ◽  
Author(s):  
Roland Asmar ◽  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Ace Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
High Cardiovascular Risk ◽  
Raas Blockade ◽  
Risk Patients ◽  
Receptor Blockers ◽  
Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Sign in / Sign up

Export Citation Format

Share Document